Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on June 1 at an average price of $547.91, for a total of about $5.2 million. After the sale, Rothblatt held 40,513 shares, a 19% reduction in the position.
- The stock was trading around $540.05, down 0.8% in the session, and remains near the upper end of its 52-week range of $272.12 to $609.35. The company has a market cap of about $22.93 billion.
- United Therapeutics recently reported mixed quarterly results, with earnings of $5.82 per share missing estimates of $7.00 and revenue of $781.5 million slightly below expectations. Despite that, analysts remain generally positive, with a consensus rating of Moderate Buy.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $547.91, for a total value of $5,205,145.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,197,477.83. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
United Therapeutics Trading Down 0.8%
United Therapeutics stock opened at $540.05 on Wednesday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock's 50 day simple moving average is $566.86 and its two-hundred day simple moving average is $516.87. The firm has a market cap of $22.93 billion, a PE ratio of 19.94, a P/E/G ratio of 1.77 and a beta of 0.57.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. During the same quarter in the prior year, the company posted $6.63 EPS. The company's revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.92 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in UTHR. Wellington Management Group LLP raised its stake in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in United Therapeutics in the 3rd quarter valued at $317,617,000. Norges Bank acquired a new position in United Therapeutics in the 4th quarter valued at $293,418,000. Avoro Capital Advisors LLC raised its stake in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company's stock valued at $387,801,000 after purchasing an additional 341,383 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the company. UBS Group upped their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Royal Bank Of Canada lowered their price objective on United Therapeutics from $707.00 to $701.00 and set an "outperform" rating on the stock in a research report on Thursday, May 7th. Cantor Fitzgerald upped their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research report on Thursday, March 12th. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They set an "outperform" rating and a $700.00 target price for the company. Finally, Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $619.42.
Get Our Latest Analysis on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
